Aptose Biosciences (APTO) investor relations material

Executive summary

• Tuspetinib is advancing in clinical trials for frontline AML therapy, showing high efficacy and safety in combination with venetoclax and azacitidine, with promising results across diverse genetic subgroups and no dose-limiting toxicities reported.

• The TUSCANY trial continues to show robust safety and response data, with updated results to be presented at EHA 2026 Congress.

• A definitive arrangement agreement was approved for acquisition by Hanmi, with shareholders to receive C$2.41 per share; closing is expected in May 2026, pending regulatory approvals, with delays possible.

• The Luxeptinib program has been returned to CrystalGenomics, ending the exclusive development agreement and transferring all associated rights and data.

• First quarter 2026 results highlighted ongoing clinical progress and corporate developments.

Financial highlights

• Net loss for Q1 2026 was $7.6 million, up from $5.5 million in Q1 2025, driven by increased R&D and G&A expenses.

• Cash and restricted cash totaled $4.1 million as of March 31, 2026, with a working capital deficit of $5.1 million and shareholders' deficit of $34.7 million.

• Research and development expenses rose to $3.6 million, primarily due to higher tuspetinib program costs.

• General and administrative expenses increased to $3.6 million, mainly from higher professional fees and regulatory costs.

• Weighted average shares outstanding increased to 2,552,429 from 2,126,287 year-over-year.

Outlook and guidance

• Management expects continued negative cash flows and does not anticipate positive cash flow from operations in the foreseeable future.

• Additional financing is necessary to meet capital requirements and continue operations; options include debt, equity, collaborations, or restructuring.

• Actively implementing cost reduction efforts to extend cash runway and continued reliance on Hanmi advances to fund operations until acquisition closes.

• The company faces substantial doubt about its ability to continue as a going concern due to limited liquidity and reliance on Hanmi advances.

• Further updates on the acquisition and clinical milestones expected in the coming months.